Issues in Oncology

Risk Factors for Immune Checkpoint Inhibitor–Related Myocarditis: An Integrative Review

Sara M. Otto, MS, APRN, FNP-BC, AOCNP®, Ashely L. Martinez, DNP, APRN, FNP-BC, AOCNP®, CBCN, CPHQ, NEA-BC, and Joyce E. Dains, DrPH, JD, APRN, FNP-BC, FNAP, FAANP, FAAN

Purpose: The purpose of this integrative literature review was to determine factors that increase the risk of immune checkpoint inhibitor (ICI)–related myocarditis in the cancer patient population. Methods: A literature review was conduc...

The Role of Echocardiogram and Cardiac Rhythm Analysis for Early Detection of Cardiac Amyloidosis

Elizabeth Hubert, APRN, FNP-C, and Joyce E. Dains, DrPH, JD, APRN, FNP-BC, FNAP, FAANP

Purpose: The purpose of this integrative review was to establish the role of cardiac rhythm analysis (electrocardiogram; EKG) and echocardiogram in increasing clinical suspicion for and earlier diagnosis of cardiac amyloidosis. Methods: ...

Cardio-Oncology Considerations in Oncologic Treatment Decisions

Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN

At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy....

Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy

Lisa Nodzon, PhD, APRN, AOCNP®, Anecita Fadol, PhD, FNP-BC, FAANP, FAAN, and Sara Tinsley, PhD, APRN, AOCN®

Cardiovascular (CV) risk mitigation is an important consideration in the management of chronic myeloid leukemia (CML) patients. Although BCR-ABL1 inhibition by tyrosine kinase inhibitors (TKI) has led to a significant improvement in prog...

Assessment of Oncology Provider Knowledge and Cardiovascular Screening Practices: A Call for Heightened Screening

Katherine Albert,(1) DNP, FNP-BC, AOCNP®, Deborah Pollard,(1) PhD, RNC-OB, CNE, IBCLC, Jennifer Klemp,(2) PhD, MPH, MA, Lavanya Kondapalli,(3) MD, and Deborah Tuffield,(1) DNP, FNP-C, CCRN

Cardiac risk factors are known to compound the development of cardiotoxicities (CTx) in patients exposed to anthracycline (ANT) chemotherapy agents. National oncology and cardiology organizations have published recommendations for cardio...

Cardio-Oncology: The Intersection Between Cardiovascular Disease and Cancer

Presented by Jessica Shank Coviello, DNP, APRN, ANP-BC, and Kejal Amin, PharmD, MBA, BCOP

Cardio-oncology is a rapidly emerging field, and advanced practitioners (APs) play key roles in the prevention, early detection, and optimal treatment of cardiotoxicities associated with cancer therapies. At JADPRO Live Virtual 2020, Jes...

Cardiac Toxicity and Anthracyclines: Mechanism, Interventions, and the Trouble With Troponin

Grace E. Thompson, MSN, AGACNP-BC, AGPCNP-BC, and Phyllis P. Wright, DNP, AGPCNP-BC, MPH

As cancer survivorship increases, clinicians need to become educated regarding the long-term effect of cancer treatments. Cancer therapeutics–related cardiac dysfunction (CTRCD) is one such sequela that contributes to significant morbidi...

Cardio-oncology: A Subspecialty in its Infancy

Cardiovascular and Cancer Risk: The Role of Cardio-oncology

Abstract Cardio-oncology is a subspecialty of cardiology. It was created to address oncology data indicating that newly developed drugs for cancer treatment were having unanticipated cardiac side effects. Cardio-oncology designs primary...

Joining Forces: Establishing a Cardio-oncology Clinic

Abstract Patients have been surviving cancer diagnoses at a steadily increasing rate over the past few decades. Despite the encouraging decline in cancer morbidity, the cardiovascular effect of some chemotherapy medications is concernin...